Myriad Genetics, Inc. MYGN

Company Overview

Myriad Genetics, Inc. is a molecular diagnostics company specializing in genetic and genomic testing to inform disease risk, diagnosis, prognosis, and treatment decisions. The company operates primarily within the precision medicine, oncology, and women’s health industries, providing clinically validated tests to healthcare providers, hospitals, and health systems. Its core offerings focus on hereditary cancer risk assessment, tumor profiling, and companion diagnostics used to guide targeted therapies.

Founded in 1991, Myriad Genetics emerged from academic research in human genetics and gained prominence through the commercialization of BRCA1 and BRCA2 hereditary cancer tests in the 1990s. Over time, the company evolved from a single-test model into a diversified diagnostics platform, expanding its portfolio through internal development and acquisitions. Following changes in the competitive and intellectual property landscape in the mid-2010s, Myriad shifted strategy toward broader test menus, international expansion, and integrated clinical decision support.